{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:31:25Z","timestamp":1793194285905,"version":"4.5.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Patients with relapsed\/refractory multiple myeloma (RRMM) have limited treatment options. Arlocabtagene autoleucel (arlo-cel; BMS-986393) is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting G protein\u2013coupled receptor class C group 5 member D (GPRC5D). This phase 1, dose-escalation\/expansion study enrolled adult patients with RRMM and \u22653 previous antimyeloma treatment regimens, including an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody. Patients (N = 84) had a median of 5 prior regimens, and 49% had previously received B-cell maturation antigen\u2013targeted therapy. Arlo-cel was administered as a single IV infusion of 25 to 450 \u00d7 106 CAR T cells. Primary end points were safety and maximum tolerated dose (MTD); secondary end points included overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Data cutoff was 23 August 2024. Cytokine release syndrome (CRS) occurred in 82% of patients, immune effector cell\u2013associated neurotoxicity syndrome in 10%, and other select neurotoxicities in 12%; most were grade 1\/2 and frequency appeared dose-dependent. One death occurred from CRS at the highest dose level. On-target\/off-tumor skin (30%), nail (19%), and oral (32%) adverse events were transient and grade 1\/2; most resolved without intervention. MTD was not reached. With a median follow-up of 16.1 months, ORR was 87% (complete response rate, 53%), median duration of response was 18.0 months, median PFS was 18.3 months (95% confidence interval, 11.8-21.9; n = 79), and 1-year OS rate was 90% (N = 84). Arlo-cel showed a manageable safety profile and deep, durable responses, with promising PFS and OS in heavily pretreated RRMM, supportive of future clinical research. This trial was registered at www.clinicaltrials.gov as NCT04674813.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025030750","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:10:37Z","timestamp":1780485037000},"page":"1240-1250","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed\/refractory multiple myeloma"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8206-8919","authenticated-orcid":false,"given":"Susan","family":"Bal","sequence":"first","affiliation":[{"name":"1Department of Hematology and Oncology, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myo","family":"Htut","sequence":"additional","affiliation":[{"name":"2Division of Myeloma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4124-4277","authenticated-orcid":false,"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[{"name":"3Myeloma Immune Effector Cell Therapy Program, Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"suffix":"Jr.","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[{"name":"4Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Gregory","sequence":"additional","affiliation":[{"name":"5Colorado Blood Cancer Institute, Sarah Cannon Cancer Network, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9888-5737","authenticated-orcid":false,"given":"Mehmet Hakan","family":"Ko\u00e7o\u011flu","sequence":"additional","affiliation":[{"name":"6University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana C.","family":"Rossi","sequence":"additional","affiliation":[{"name":"7Center of Excellence for Multiple Myeloma, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9133-9813","authenticated-orcid":false,"given":"Tom","family":"Martin","sequence":"additional","affiliation":[{"name":"8Hematology, Blood & Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel N.","family":"Egan","sequence":"additional","affiliation":[{"name":"9Department of Hematology Oncology, Swedish Cancer Institute, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5362-2469","authenticated-orcid":false,"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxiang","family":"Hu","sequence":"additional","affiliation":[{"name":"10Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2067-5261","authenticated-orcid":false,"given":"Jinjie","family":"Chen","sequence":"additional","affiliation":[{"name":"10Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyi","family":"Li","sequence":"additional","affiliation":[{"name":"10Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Kelly","sequence":"additional","affiliation":[{"name":"10Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomey","family":"Sarkis","sequence":"additional","affiliation":[{"name":"10Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safiyyah","family":"Ziyad","sequence":"additional","affiliation":[{"name":"10Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5165-5769","authenticated-orcid":false,"given":"Kristina M.","family":"Jordahl","sequence":"additional","affiliation":[{"name":"10Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ming","family":"Kao","sequence":"additional","affiliation":[{"name":"10Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison J.","family":"Kaeding","sequence":"additional","affiliation":[{"name":"10Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Burgess","sequence":"additional","affiliation":[{"name":"10Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4362-0376","authenticated-orcid":false,"given":"Jesus G.","family":"Berdeja","sequence":"additional","affiliation":[{"name":"11Multiple Myeloma Research, Greco-Hainsworth Center for Research at Tennessee Oncology, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2026090311215136900_bib1","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1179\/1607845413Y.0000000079","article-title":"GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells","volume":"18","author":"Cohen","year":"2013","journal-title":"Hematology"},{"issue":"485","key":"2026090311215136900_bib2","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"issue":"15","key":"2026090311215136900_bib3","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood.2019003342","article-title":"A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2026090311215136900_bib4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","article-title":"The RAIG family member, GPRC5D, is associated with hard-keratinized structures","volume":"122","author":"Inoue","year":"2004","journal-title":"J Invest Dermatol"},{"key":"2026090311215136900_bib5","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/S2152-2650(21)02229-1","article-title":"Normal human tissue expression of G-protein coupled receptor 5D (GPRC5D), a promising novel target for multiple myeloma, is restricted to plasma cells and hard keratinized tissues","volume":"21","author":"Goldsmith","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"2026090311215136900_bib6","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"2026090311215136900_bib7","author":"TALVEY\u2122 (talquetamab-tgvs)","year":"2023"},{"issue":"13","key":"2026090311215136900_bib8","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"2026090311215136900_bib9","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"issue":"14","key":"2026090311215136900_bib10","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1200\/JCO.22.01824","article-title":"Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase II trial","volume":"41","author":"Xia","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026090311215136900_bib11","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1016\/S2352-3026(24)00176-5","article-title":"Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial","volume":"11","author":"Zhou","year":"2024","journal-title":"Lancet Haematol"},{"issue":"13","key":"2026090311215136900_bib12","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/0008-5472.CAN-11-0422","article-title":"In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)","volume":"71","author":"Song","year":"2011","journal-title":"Cancer Res"},{"issue":"8","key":"2026090311215136900_bib13","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"2026090311215136900_bib14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"2026090311215136900_bib15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2026090311215136900_bib16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials","volume":"35","author":"Costa","year":"2021","journal-title":"Leukemia"},{"key":"2026090311215136900_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cct.2017.04.006","article-title":"A Bayesian interval dose-finding design addressing Ockham's razor: mTPI-2","volume":"58","author":"Guo","year":"2017","journal-title":"Contemp Clin Trials"},{"issue":"9","key":"2026090311215136900_bib18","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2023012066","article-title":"Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma","volume":"8","author":"Reyes","year":"2024","journal-title":"Blood Adv"},{"issue":"7","key":"2026090311215136900_bib19","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy","volume":"141","author":"Van Oekelen","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2026090311215136900_bib20","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"2026090311215136900_bib21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-021-00507-2","article-title":"KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","volume":"11","author":"Jagannath","year":"2021","journal-title":"Blood Cancer J"},{"issue":"6","key":"2026090311215136900_bib22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"2026090311215136900_bib23","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"2026090311215136900_bib24","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026090311215136900_bib25","author":"Harrison","year":"27-30  2023"},{"issue":"10297","key":"2026090311215136900_bib26","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"2026090311215136900_bib27","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO-24-01785","article-title":"Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: an updated analysis","volume":"43","author":"Jurgens","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026090311215136900_bib28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"2026090311215136900_bib29","author":"Carlo-Stella","year":"10-13  2022"},{"key":"2026090311215136900_bib30","unstructured":"A study to evaluate the safety, effectiveness and tolerable dose of BMS-986393 in novel combinations in participants with relapsed and\/or refractory multiple myeloma. ClinicalTrials.gov identifier: NCT06121843. Updated 18 February 2026. Accessed 8 October 2024. https:\/\/clinicaltrials.gov\/study\/NCT06121843."},{"key":"2026090311215136900_bib31","unstructured":"Study of BMS-986393 a GPRC5D-directed CAR T cell therapy in adult participants with relapsed or refractory multiple myeloma (QUINTESSENTIAL). ClinicalTrials.gov identifier: NCT06297226. Updated 28 May 2026. Accessed 3 June 2024. https:\/\/clinicaltrials.gov\/study\/NCT06297226."},{"key":"2026090311215136900_bib32","unstructured":"A\u00a0study to compare the efficacy and safety of BMS-986393 versus standard regimens in adult participants with relapsed or refractory and lenalidomide-refractory multiple myeloma (QUINTESSENTIAL-2). ClinicalTrials.gov identifier: NCT06615479. Updated 04 June 2026. Accessed 3 December 2024. https:\/\/clinicaltrials.gov\/study\/NCT06615479."},{"issue":"6","key":"2026090311215136900_bib33","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M15-0288","article-title":"Good Publication Practice for communicating company-sponsored medical research: GPP3","volume":"163","author":"Battisti","year":"2015","journal-title":"Annals of Internal Medicine"},{"issue":"suppl 1","key":"2026090311215136900_bib34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2023-181857","article-title":"BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 study [abstract]","volume":"142","author":"Bal","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026090311215136900_bib35","first-page":"951","article-title":"Safety and preliminary efficacy of BMS-986393, a GPRC5D CAR T-cell therapy, in patients with relapsed\/refractory multiple myeloma and 1-3 prior regimens: first results from a phase 1 study","volume":"8","author":"Nadeem","year":"2024","journal-title":"HemaSphere"},{"issue":"suppl 1","key":"2026090311215136900_bib36","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/blood-2024-201356","article-title":"Efficacy and safety with extended follow-up in a phase 1 study of BMS-986393, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T-cell therapy, in patients with heavily pretreated relapsed\/refractory multiple myeloma [abstract]","volume":"144","author":"Bal","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026090311215136900_bib37","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2024-203279","article-title":"BMS-986393, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T-cell therapy in patients with relapsed\/refractory multiple myeloma and 1-3 prior regimens: updated phase 1 safety and efficacy results","volume":"144","author":"Bal","year":"2024","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/10\/1240\/2541918\/blood_bld-2025-030750-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/10\/1240\/2541918\/blood_bld-2025-030750-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:22:00Z","timestamp":1788448920000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/10\/1240\/568830\/Arlocabtagene-autoleucel-a-GPRC5D-targeted-CAR-T"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025030750","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,3]]},"published":{"date-parts":[[2026,9,3]]}}}